home / lobbying

lobbying_activities

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

305 rows where filing_period = "second_quarter", filing_year = 2019 and issue_code = "PHA" sorted by filing_year descending

✎ View and edit SQL

This data as json, CSV (advanced)

Suggested facets: filing_type, is_termination, received_date (date)

issue_code 1

  • PHA · 305 ✖

filing_year 1

  • 2019 · 305 ✖

filing_period 1

  • second_quarter · 305 ✖
id filing_uuid filing_type registrant_name registrant_id client_name filing_year ▲ filing_period issue_code specific_issues government_entities income_amount expense_amount is_no_activity is_termination received_date
2295469 RED+BLUE STRATEGIES 503a8908-c2e3-481b-b88e-1ead61f1a6a4 2T RED+BLUE STRATEGIES 400693064 CIGNA CORPORATION 2019 second_quarter PHA Issues related to Trump Administration proposals and regulations regarding drug pricing reforms, regulations regarding rebates, and related guidances focused on affordability and accessibility to prescription medications in the United States. Proposals, guidances and call letters and impacting Medicare Part D and the role of Pharmacy Benefit Managers. Issues related to transparency in the prescription drug marketplaces including new technologies to improve physician and patient access to real time pricing questions and concerns. Issues related to utilization and access to e- prescribing tools. Issues focused on the promotion of fair competition in the prescription drug market place, including policies focused on patents, biosimilars and generic medications. SENATE 20000   0 1 2019-05-01T15:36:02.127000-04:00
2298640 AMERICAN COLLEGE OF CLINICAL PHARMACY 654ca888-9145-4b8c-b9af-df6f5c31057f Q2 AMERICAN COLLEGE OF CLINICAL PHARMACY 57258 AMERICAN COLLEGE OF CLINICAL PHARMACY 2019 second_quarter PHA Coverage for direct patient care services of qualified clinical pharmacists under Medicare and other public health programs. Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE   144981 0 0 2019-07-02T10:25:36.093000-04:00
2298732 4C COMMUNICATIONS, INC. 5f53c9e6-1180-4fe7-b885-215d33f59cd5 Q2 4C COMMUNICATIONS, INC. 323717 HEALTHCARE LEADERSHIP COUNCIL 2019 second_quarter PHA Discussion on pharmaceutical drug pricing HOUSE OF REPRESENTATIVES,SENATE     0 0 2019-07-02T11:35:05.240000-04:00
2298943 AMERICAN SOCIETY FOR DERMATOLOGIC SURGERY ASSOCIATION 81093bec-49c1-478f-a29c-f838c6f65ccc Q2 AMERICAN SOCIETY FOR DERMATOLOGIC SURGERY ASSOCIATION 401103437 AMERICAN SOCIETY FOR DERMATOLOGIC SURGERY ASSOCIATION 2019 second_quarter PHA Compounding Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,Veterans Affairs, Dept of (VA)     0 0 2019-07-02T16:04:54.367000-04:00
2299238 REPUBLIC CONSULTING, LLC fb931655-b239-4d2d-9578-cabb0e348eb3 Q2 REPUBLIC CONSULTING, LLC 401016871 IQVIA 2019 second_quarter PHA Monitor Data and Science Policy. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 110000   0 0 2019-07-03T12:19:29.370000-04:00
2299243 REPUBLIC CONSULTING, LLC d267212c-dc2b-4ffe-b706-5484bfb3431f 2A REPUBLIC CONSULTING, LLC 401016871 IQVIA 2019 second_quarter PHA Monitor Data and Science Policy. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2019-07-03T12:31:31.197000-04:00
2299394 RUBICON ADVISORS, LLC 5228923d-353d-4158-a813-421829ac61d0 Q2 RUBICON ADVISORS, LLC 315091 DYNAVAX TECHNOLOGIES 2019 second_quarter PHA Prescription Drug User Fee HOUSE OF REPRESENTATIVES,SENATE 45000   0 0 2019-07-03T15:48:39.267000-04:00
2299398 RUBICON ADVISORS, LLC da389119-ede3-4e9e-b809-3d171f89d4f0 Q2 RUBICON ADVISORS, LLC 315091 DR. REDDY'S LABORATORIES, LTD 2019 second_quarter PHA Prescription Drug User Fee (PDUFA) re authorization.Generic Drug User Fee Act (GDUFA) re authorization. Border Adjustment Tax(BAT)issues Drug Enforcement Administration (DEA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE 45000   0 0 2019-07-03T15:53:41.847000-04:00
2299399 RUBICON ADVISORS, LLC 6206c733-39f9-4922-811f-b7f4dfe16e4f Q2 RUBICON ADVISORS, LLC 315091 CONSCIOUS DISCIPLINE 2019 second_quarter PHA Medicare HOUSE OF REPRESENTATIVES,SENATE 37500   0 0 2019-07-03T15:55:42.737000-04:00
2299620 HOLLAND & KNIGHT LLP 9bae203a-1311-46ef-a966-5cea4d90f4cc Q2 HOLLAND & KNIGHT LLP 18466 TEVA PHARMACEUTICALS USA, INC. 2019 second_quarter PHA Drug pricing; Intellectual property. HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2019-07-05T13:48:02.330000-04:00
2299908 POLITICAL CAPITAL, LLC 1a1a2257-4aaa-44b0-9e22-7f508acf4af3 Q2 POLITICAL CAPITAL, LLC 401104260 MEDISCA INC 2019 second_quarter PHA Guidance documents, compounding pharmacy, appropriations language. Executive Office of the President (EOP),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 45000   0 0 2019-07-08T13:30:39.493000-04:00
2299914 POLITICAL CAPITAL, LLC 87613ae5-42dc-468b-980a-6ab611edd1f3 Q2 POLITICAL CAPITAL, LLC 401104260 PINE PHARMACEUTICALS 2019 second_quarter PHA Guidance documents, compounding pharmacy, appropriations language. Executive Office of the President (EOP),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2019-07-08T13:37:42.853000-04:00
2299916 POLITICAL CAPITAL, LLC c331a9bf-8b5e-4837-96d0-790782e77b63 Q2 POLITICAL CAPITAL, LLC 401104260 STOKES PHARMACY 2019 second_quarter PHA Compounding Executive Office of the President (EOP),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2019-07-08T13:38:43.447000-04:00
2299918 POLITICAL CAPITAL, LLC 5d3094f8-96b9-40a3-9794-559d1f41d090 Q2 POLITICAL CAPITAL, LLC 401104260 KRS GLOBAL BIOTECHNOLOGY INC 2019 second_quarter PHA Compounding Executive Office of the President (EOP),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE     0 0 2019-07-08T13:39:44.307000-04:00
2300051 RED+BLUE STRATEGIES 3513e077-b0c3-4193-8f59-30b1f8fb00cb Q2 RED+BLUE STRATEGIES 400693064 PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA) 2019 second_quarter PHA S. 1895 - The Lower Health Costs Act of 2019 - Issues related to the treatment of rebates in the prescription drug arena and transparency of information and data pertaining to the buying and selling of prescription medicines. CREATES Act (S.340/ H.R. 965) - Issues related to reducing prices and increasing competition in the prescription drug marketplace. C-THRU Act (S. 476) - Issues related to transparency in the PBM space and ensuring that tools to decrease the cost of prescription medications are maintained. HHS rules and regulations related to the cost of prescription drugs, including, but not limited to, limiting rebates in the Medicare and Medicaid prescription drug benefits. Policies related to the reform of Medicare Part B and D specific to the price of prescription medications. Executive Office of the President (EOP),HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2019-07-08T20:27:44.267000-04:00
2300052 RED+BLUE STRATEGIES 64ec0074-e5ea-4046-b9d5-148b3d507cc8 Q2 RED+BLUE STRATEGIES 400693064 PEW CHARITABLE TRUSTS 2019 second_quarter PHA H.R. 2482 - The Mainstreaming Addition Treatment Act of 2019 - Support for policies increasing the ability to access MAT to treat addiction. H.R. 3443 - The OTC Monograph Safety Innovation and Reform Act of 2019 - Support for policies that enable OTC monograph reform. Issues related to the implementation on the SUPPORT Act (P.L. 115-271) regarding MAT treatment. Issues related to curbing antibiotic resistance. HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2019-07-08T20:37:45.253000-04:00
2300801 PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION 1e036ea8-07a0-4277-b285-27e96923ff20 Q2 PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION 401103605 PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION 2019 second_quarter PHA Discussed potential solutions for drug shortages, in addition to general education about role of bio/pharmaceutical contract manufacturing organizations and development service providers. HOUSE OF REPRESENTATIVES,SENATE   50000 0 0 2019-07-10T10:58:10.707000-04:00
2300891 ACG ADVOCACY de96f6ca-f65d-41ac-8181-1b0d13829bb2 Q2 ACG ADVOCACY 2057 WALGREEN CO. 2019 second_quarter PHA Drug Pricing Policy Issues. Data privacy and DIR fee reform. HOUSE OF REPRESENTATIVES,SENATE 80000   0 0 2019-07-10T12:18:08.027000-04:00
2301160 MARSHALL & POPP, LLC 59077809-defa-4eb7-9a9e-7c3b3eb89892 Q2 MARSHALL & POPP, LLC 401105121 GENENTECH, INC. 2019 second_quarter PHA Prescription drug value issues. Biosimilars. Importation of prescription drugs. 340B issues. FDA regulatory issues, including the International Pricing Index and Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals. Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Economic Council (NEC),Office of Management & Budget (OMB),White House Office 20000   0 0 2019-07-10T16:37:43.237000-04:00
2301162 MARSHALL & POPP, LLC 726e30b7-cf9c-4656-9ad5-8969cf73db37 Q2 MARSHALL & POPP, LLC 401105121 GENENTECH, INC. 2019 second_quarter PHA Prescription drug value issues. Biosimilars. Importation of prescription drugs. 340B issues. FDA regulatory issues, including the International Pricing Index and Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals. Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Economic Council (NEC),Office of Management & Budget (OMB),White House Office 60000   0 0 2019-07-10T16:38:44.113000-04:00
2301179 MARSHALL & POPP, LLC b18c0852-5932-487d-b51a-0f59c5868dbf Q2 MARSHALL & POPP, LLC 401105121 PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA 2019 second_quarter PHA Prescription drug value issues. Biosimilars. Importation of prescription drugs. 340B issues. FDA regulatory issues, including the International Pricing Index and Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals. Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Economic Council (NEC),Office of Management & Budget (OMB),White House Office 50000   0 0 2019-07-10T16:52:54.943000-04:00
2301181 MARSHALL & POPP, LLC d79ecd4e-e44b-4d9e-ad14-a8e692be2322 Q2 MARSHALL & POPP, LLC 401105121 SANOFI U.S. SERVICES, INC. 2019 second_quarter PHA Prescription drug value issues. Biosimilars. Importation of prescription drugs. 340B issues. FDA regulatory issues, including the International Pricing Index and Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals. Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Economic Council (NEC),Office of Management & Budget (OMB),White House Office 40000   0 0 2019-07-10T16:56:55.787000-04:00
2301292 RED+BLUE STRATEGIES a0878609-ac72-4524-8e58-ad4f6ca46dde Q2 RED+BLUE STRATEGIES 400693064 COHERUS BIOSCIENCES 2019 second_quarter PHA S. 1895 - The Lowering Health Care Costs Act - provisions related to creating a fair playing field for biosimilars in the United States. Issues related to improving and expanding the biosimilars marketplace through policies that will create a more even playing field for biosimilars in the overall prescription drug marketplace in the United States. Areas of focus include policies regarding patent law, public and private reimbursement and FDA interchangeability standards. Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),SENATE 60000   0 0 2019-07-11T10:06:10.783000-04:00
2301336 POLSINELLI PC 24f41c09-609b-415c-998b-d28bd2562574 Q2 POLSINELLI PC 314911 TEVA PHARMACEUTICALS USA, INC. 2019 second_quarter PHA H.R.938, Bringing Low Cost Options & Competition While Keeping Incentives for New Generics (BLOCKING) Act H.R.965/ S.340, CREATES Act H.R.1503, Orange Book Transparency Act H.R.1520, Purple Book Continuity Act H.R.2374/ S.1224, Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (STALLING) Act H.R.2375/ S.64, Preserve Access to Affordable Generics and Biosimilars Act H.R.2376/ S.1227, Prescription Pricing for the People Act S.1416, Affordable Prescriptions for Patients Act S.1895, Lower Health Care Costs Act H.R. 1499, Protecting Consumer Access to Generic Drugs Act Administration review of drug pricing policies HOUSE OF REPRESENTATIVES,SENATE 75000   0 0 2019-07-11T10:40:32.103000-04:00
2301432 MCDERMOTT+ LLC 480e5332-57fc-4ec6-9c16-3df08929d923 Q2 MCDERMOTT+ LLC 401103287 ALLIANCE FOR RURAL HOSPITAL ACCESS 2019 second_quarter PHA Amendments to Section 340B of the Public Health Service Act regarding eligibility for rural referral centers and sole community hospitals in the federal discount drug purchasing program. Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2019-07-11T11:25:21.577000-04:00
2301504 JOHNSON MATTHEY INC. 64a4424d-470c-410a-9c80-5bdd0d5b3a45 Q2 JOHNSON MATTHEY INC. 401104441 JOHNSON MATTHEY INC. 2019 second_quarter PHA H.R. 965 and S. 340 CREATES Act of 2019, provisions relating to improving the process by which generic manufacturers could obtain sufficient quantities of brand drug samples for testing thereby deterring practices that impede generic entry to the market. H.R. 938 BLOCKING Act of 2019, provisions relating to discouraging parking of the 180-day exclusivity period for first generic drugmakers challenging pharmaceutical patents. S. 1895 Lower Health Care Costs Act of 2019, provisions relating to modifications to the exclusivity benefits afforded to first-to-file generic drugmakers. H.R. 990 and S. 344 Hatch-Waxman Integrity Act of 2019, provisions relating to limit generic companies' ability to initiate inter partes review. H.R. 1520 Purple Book Continuity Act, provisions relating to codifying publication of patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book. H.R. 1503 Orange Book Transparency Act, provisions relating to requiring manufacturers to share complete and timely information with FDA, as well as ensuring that patents listed in the Orange Book are relevant to the approved drug product. H.R. 1499 Protecting Consumer Access to Generic Drugs Act, provisions relating to the prohibition of agreements between brand drug and generic manufacturers that pay generic manufacturers to keep the generic equivalent off the market. H.R. 1781 Payment Commission Data, provisions relating to providing drug pricing and rebate data access the Medicare Payment Advisory Commission and Medicaid and CHIP Payment and Access Commission to help these commissions better understand the true costs of prescription drugs to consumers and taxpayers. Environmental Protection Agency (EPA),HOUSE OF REPRESENTATIVES,SENATE   20000 0 0 2019-07-11T12:26:55.100000-04:00
2301524 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. a20727ee-506e-4a11-9570-efe45f613793 Q2 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 8511 NATIONAL HEMOPHILIA FOUNDATION 2019 second_quarter PHA Issues related to hemophilia treatments, specialty pharmacies and the 340B drug purchasing programs. Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE 50000   0 0 2019-07-11T12:48:03.180000-04:00
2301927 SIMS STRATEGIES, LLC 0a447c8d-e561-4fe2-a80b-ee897d991957 Q2 SIMS STRATEGIES, LLC 401104546 GLAXOSMITHKLINE, INC. 2019 second_quarter PHA Education and importance of various pharmaceutical industry issues, including issues affecting vaccines and shortages. SENATE 40000   0 0 2019-07-11T18:12:01.217000-04:00
2302060 CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER f839166e-2a0f-4f97-8699-73e9b3eace56 Q2 CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER 312496 CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER 2019 second_quarter PHA Drug pricing, PCORI re-authorization, 340B Agency for Healthcare Research & Quality (AHRQ),Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE,White House Office   39050 0 0 2019-07-12T09:53:14.490000-04:00
2302083 MCGUIREWOODS CONSULTING (A SUBSIDIARY OF MCGUIREWOODS LLP) b472c65c-87e4-47a6-9679-90bac0f04df1 Q2 MCGUIREWOODS CONSULTING (A SUBSIDIARY OF MCGUIREWOODS LLP) 24486 INOVIO PHARMACEUTICALS 2019 second_quarter PHA Government Relations Services including developing strategies to achieve legislative goals, inclusion of MERS on list of neglected diseases at FDA Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2019-07-12T10:15:25.587000-04:00
2302482 HANCE SCARBOROUGH 7c5bd5d4-6a53-46f9-b45b-3712879730d8 Q2 HANCE SCARBOROUGH 17443 TITAN PHARMACEUTICALS, INC. 2019 second_quarter PHA Medicare/Medicaid drug coverage, opioid addiction policy. HOUSE OF REPRESENTATIVES,SENATE     0 0 2019-07-12T14:12:03.647000-04:00
2302488 HANCE SCARBOROUGH 9d9b9fb0-8299-4284-bbcd-f964cb455000 Q2 HANCE SCARBOROUGH 17443 ALLIANCE FOR PHARMACY COMPOUNDING 2019 second_quarter PHA Issues related to the regulation of pharmacy compounding. HR 1959 Preserving Patient Access to Compounded Medications Act. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2019-07-12T14:15:05.100000-04:00
2302825 340B HEALTH 0ec1ceb2-63d0-472f-83da-fa730683ca4a Q2 340B HEALTH 316434 340B HEALTH 2019 second_quarter PHA The 340B Drug Pricing Program; FY 2020 L-HHS Appropriations. HOUSE OF REPRESENTATIVES,SENATE   234868 0 0 2019-07-12T17:32:20.407000-04:00
2302894 INDEPENDENT PHARMACY COOPERATIVE 24481571-ef25-443d-aa95-669c02c9e8b0 Q2 INDEPENDENT PHARMACY COOPERATIVE 313098 INDEPENDENT PHARMACY COOPERATIVE 2019 second_quarter PHA Improving Transparency and Accuracy in Medicare Part D Spending Act S.988/ HR 803-IPC supports all pharmacy price concessions be reflected at the point-of-sale. Proposed Regulation CMS-4180-P Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses. IPC supports. Proposed Regulation - OIG-0936-P Fraud and Abuse Removal of Federal Social Security Act Safe Harbor Protections for Prescription Drug Manufacturer Rebates and Safe Harbor Protections for Prescription Drug Point-of-Sale Price Reductions-IPC supports if a reasonable timeline is given to implement. Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE   30000 0 0 2019-07-13T13:24:31.993000-04:00
2303003 CONNECT 4 STRATEGIES, LLC c9e32859-57cc-40b4-a5f5-74e1b88cd3b3 Q2 CONNECT 4 STRATEGIES, LLC 401103720 OREXO US, INC. 2019 second_quarter PHA Medicare and Medicaid access Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2019-07-14T14:24:43.807000-04:00
2303006 CONNECT 4 STRATEGIES, LLC d14a15af-81eb-4bed-8ea1-45ebe9daff98 Q2 CONNECT 4 STRATEGIES, LLC 401103720 RECORDATI RARE DISEASES 2019 second_quarter PHA CMS Issues Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2019-07-14T14:35:45.950000-04:00
2303007 CONNECT 4 STRATEGIES, LLC a586770b-16f2-46ba-8380-4b0324d2d0ba Q2 CONNECT 4 STRATEGIES, LLC 401103720 AKCEA THERAPEUTICS, INC. 2019 second_quarter PHA FDA drug approval issues Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 45000   0 0 2019-07-14T14:39:46.793000-04:00
2303008 CONNECT 4 STRATEGIES, LLC 79a44dd6-4655-4c10-a5c6-30aba331ac8e 2A CONNECT 4 STRATEGIES, LLC 401103720 RECORDATI RARE DISEASES 2019 second_quarter PHA CMS Issues Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2019-07-14T14:43:47.577000-04:00
2303096 KEEFE STRATEGIES LLC (FKA KEEFE SINGISER PARTNERS) 230f6dd5-d11f-4be6-bdbc-5c70a3c617f5 Q2 KEEFE STRATEGIES LLC (FKA KEEFE SINGISER PARTNERS) 401105192 CVS HEALTH 2019 second_quarter PHA Issues encompassing general education regarding the pharmacy benefit manager/pharmacy industry. Issues related to access and affordability of health care. Issues related to the proposed CVS-Aetna merger. HOUSE OF REPRESENTATIVES 45000   0 0 2019-07-15T08:40:29.910000-04:00
2303233 KOUNTOUPES DENHAM CARR & REID, LLC d4198ab7-996a-4639-a39b-328a4e212db2 Q2 KOUNTOUPES DENHAM CARR & REID, LLC 320918 CENCORA INC. (FORMERLY AMERISOURCEBERGEN CORPORATION) 2019 second_quarter PHA Issues related to drug pricing in the pharmaceutical supply chain. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2019-07-15T11:04:32.583000-04:00
2303555 NATIONAL ASSOCIATION OF CHAIN DRUG STORES a179af30-ad8f-4053-8623-3259abffee7a Q2 NATIONAL ASSOCIATION OF CHAIN DRUG STORES 26672 NATIONAL ASSOCIATION OF CHAIN DRUG STORES 2019 second_quarter PHA H.R. 1614 A bill to amend the Controlled Substances Act to establish additional registration requirements for prescribers of opioids, and for other purposes S. 724 A bill to amend the Controlled Substances Act to establish additional registration requirements for prescribers of opioids, and for other purposes S.340 CREATES Act of 2019 H.R. 985 FAST Generics Act of 2019 S.640 Phair Pricing Act of 2019 S. 97 Affordable and Safe Prescription Drug Importation Act S. 61 Safe and Affordable Drugs from Canada Act of 2019 H.R. 1034 Phair Pricing Act of 2019 H.R. 965 CREATES Act of 2019 H.R. 1478 Affordable Insulin Act of 2019 H.R. 447 Affordable and Safe Prescription Drug Importation Act H.R. 1499 Protecting Consumer Access to Generic Drugs Act H.R. 3417 The Beneficiary Education Tools, Telehealth, and Extenders Re-authorization Act of 2019 H.R. 2296 Fair Accountability and Innovative Research Drug Pricing (FAIR Drug Pricing) Act of 2019 H.R. 1607 Fairness to Pet Owners Act H.R. 3379 Priced Relief, Innovation, and Competition for Essential Drugs (PRICED) Act H.R. 478 Safe and Affordable Drugs from Canada Act of 2019 HOUSE OF REPRESENTATIVES,SENATE   400000 0 0 2019-07-15T13:25:27.187000-04:00
2303767 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. dc12826f-3363-4409-a808-47d781645549 Q2 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 8511 NATIONAL ASSOCIATION OF EPILEPSY CENTERS 2019 second_quarter PHA Issues related to anti-epileptic drugs. Agency for Healthcare Research & Quality (AHRQ),Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE 10000   0 0 2019-07-15T14:58:46.683000-04:00
2303778 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 02cfcc66-7b5e-4d09-94b7-24e94e836b00 Q2 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 8511 AMERICAN SOCIETY OF HEMATOLOGY 2019 second_quarter PHA HR 1409, Cancer Drug Coverage Parity Act Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE 30000   0 0 2019-07-15T15:00:50.497000-04:00
2303797 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 8ef8af19-4b5a-45d2-ae39-ff89555ef1c9 Q2 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 8511 THE HEMOPHILIA ALLIANCE 2019 second_quarter PHA Issues related to the 340B drug discount program and drug pricing policies Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2019-07-15T15:03:54.277000-04:00
2303926 KOUNTOUPES DENHAM CARR & REID, LLC 8713d6ba-50ec-474c-a3df-eb276796ef09 Q2 KOUNTOUPES DENHAM CARR & REID, LLC 320918 BLOOD CANCER UNITED (FORMERLY REPORTED ASTHE LEUKEMIA AND LYMPHOMA SOCIETY) 2019 second_quarter PHA Issues related to the cost of care and protecting patient access to blood cancer treatment. Issues related to specialty drug tiers. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2019-07-15T15:33:41.157000-04:00
2303990 NVG, LLC 520e45fa-396b-4eea-934d-6c179f5076a5 Q2 NVG, LLC 76833 MANATT, PHELPS AND PHILLIPS, LLP (ON BEHALF OF NEKTAR THERAPEUTICS) 2019 second_quarter PHA FDA oversight of certain pain reliever products. HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2019-07-15T16:03:09.817000-04:00
2304356 LINCOLN PARK GROUP L.L.C. 05602b5f-97e4-48b1-a940-d79e18099e3e Q2 LINCOLN PARK GROUP L.L.C. 401104374 CANADIAN INTERNATIONAL PHARMACY ASSOCIATION 2019 second_quarter PHA Support for S. 97/HR 447 Affordable and Safe Prescription Drug Importation Act and S. 61/HR 447 Safe and Affordable Drugs from Canada Act; issues related to personal drug importation. HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2019-07-16T09:13:27.290000-04:00
2304590 CARD & ASSOCIATES, LLC e2ff7662-3e0f-40a0-83ae-a0dded12fc7c Q2 CARD & ASSOCIATES, LLC 84217 AMAZON.COM (FRA PILLPACK AN AMAZON COMPANY) 2019 second_quarter PHA Educate Members on pharmacy contracting with pharmacy benefit managers Monitoring legislation on drug price transparency and market access issues S 1895 Lower Healthcare Costs Act HR 2296 Fair Accountability and Innovative Research Drug Pricing Act HR 2376 Prescription Pricing for the People Act HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2019-07-16T10:38:51.637000-04:00
2304749 AMERICAN VETERINARY MEDICAL ASSOCIATION 95ffed18-b16f-4c5e-b3bd-1e7f6a19a10a Q2 AMERICAN VETERINARY MEDICAL ASSOCIATION 3630 AMERICAN VETERINARY MEDICAL ASSOCIATION 2019 second_quarter PHA H.R.1607/S.1290 Fairness to Pet Owners Act HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),SENATE   230000 0 0 2019-07-16T11:38:56.893000-04:00
2304812 KOUNTOUPES DENHAM CARR & REID, LLC 543664dc-2a29-4721-aea6-174049919d09 Q2 KOUNTOUPES DENHAM CARR & REID, LLC 320918 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 2019 second_quarter PHA General issues related to over the counter pharmaceuticals. Issues related to draft legislation addressing the over the counter drug monograph process including H.R.269, the Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 and H. R. 3443, the Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2019-07-16T11:49:18.487000-04:00
2304867 MCDERMOTT WILL & SCHULTE LLP 222bd1ca-71eb-4cba-95d5-ce032f3442d5 Q2 MCDERMOTT WILL & SCHULTE LLP 24338 MAXOR NATIONAL PHARMACY SERVICES, LLC 2019 second_quarter PHA Efforts to monitor and address pharmacy and drug pricing-related legislative and regulatory proposals, including, but not limited to, the 340B Program. HOUSE OF REPRESENTATIVES,SENATE,Veterans Affairs, Dept of (VA) 30000   0 0 2019-07-16T12:06:48.240000-04:00
2305079 ISEMAN & ASSOCIATES LLC 2a0cf943-8a71-46d1-8dcb-4e56f4f9cc37 Q2 ISEMAN & ASSOCIATES LLC 401103582 TICHENOR VENTURES, LLC 2019 second_quarter PHA Monitoring biotech legislation; prescription drug prices HOUSE OF REPRESENTATIVES,SENATE 12500   0 0 2019-07-16T13:35:15.703000-04:00
2305327 TAUZIN STRATEGIC NETWORKS 134d4ff9-e515-40b0-ab30-55547aa7a2be Q2 TAUZIN STRATEGIC NETWORKS 400786367 CAPTURERX 2019 second_quarter PHA Issues related to the 340b program HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2019-07-16T14:28:00.593000-04:00
2305449 BROWN & FORTUNATO, P.C. afb6e336-7be2-4e14-b265-b09d403482d3 Q2 BROWN & FORTUNATO, P.C. 401104878 PROMPTCARE COMPANIES, INC. 2019 second_quarter PHA Issues related to Medicare home infusion therapy benefit and other health care issues. Issues related to the Medicare DMEPOS competitive bidding program. Centers For Medicare and Medicaid Services (CMS) 12000   0 0 2019-07-16T14:53:45.303000-04:00
2305492 CONNECT 4 STRATEGIES, LLC 73851b9a-8498-4d7d-9880-6df4cdc2c44c Q2 CONNECT 4 STRATEGIES, LLC 401103720 FERRING PHARMACEUTICALS, INC. 2019 second_quarter PHA Medicare issues Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2019-07-16T15:05:00.477000-04:00
2305867 ELI LILLY AND COMPANY b0cbf4c6-e908-4d38-a3c4-217fc3800310 Q2 ELI LILLY AND COMPANY 13392 ELI LILLY AND COMPANY 2019 second_quarter PHA Hospital discounts; 340B program Commerce, Dept of (DOC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),Office of Management & Budget (OMB),SENATE,State, Dept of (DOS),U.S. Trade Representative (USTR)   2330000 0 0 2019-07-16T16:38:08.143000-04:00
2306510 NATIONAL GROCERS ASSOCIATION cade41e7-bc5a-4510-8beb-e5120e149097 Q2 NATIONAL GROCERS ASSOCIATION 27924 NATIONAL GROCERS ASSOCIATION 2019 second_quarter PHA Pharmacy DIR Fee Reform Modernizing Part D and Medicare Advantage To Lower Drug Prices and Reduce Out-of-Pocket Expenses (CMS-4180-F) H.R.1034 - Phair Pricing Act of 2019 S.640 - Phair Pricing Act of 2019 S.476 - Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019 Agriculture, Dept of (USDA),Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Federal Reserve System,Federal Trade Commission (FTC),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),Office of Management & Budget (OMB),SENATE   110000 0 0 2019-07-17T10:54:06.840000-04:00
2306686 THE ROTUNDA GROUP LLC a99c7619-6022-4bf3-a9c8-72b00a0c598c Q2 THE ROTUNDA GROUP LLC 401104124 MAGNA PHARMACEUTICALS, INC. 2019 second_quarter PHA illegal drug control policy HOUSE OF REPRESENTATIVES,SENATE     0 0 2019-07-17T11:25:25.767000-04:00
2306841 ZHF CONSULTING LLC bc97c245-2aeb-400a-9537-be730d37d02c Q2 ZHF CONSULTING LLC 401103689 MEDISCA, INC. 2019 second_quarter PHA Opioid crisis/alternative pain medication/including defense   22500   0 0 2019-07-17T11:51:11.943000-04:00
2306920 NATIONAL RURAL HEALTH ASSOCATION dba1c35c-76fc-455b-aa8e-238c29e6f25a Q2 NATIONAL RURAL HEALTH ASSOCATION 53048 NATIONAL RURAL HEALTH ASSOCATION 2019 second_quarter PHA The 340B Program and drug pricing Agriculture, Dept of (USDA),HOUSE OF REPRESENTATIVES,SENATE   16182 0 0 2019-07-17T12:08:35.570000-04:00
2307203 ALLERGAN USA, INC. 7a4307b4-b8f5-4e35-be19-216455ee40d9 Q2 ALLERGAN USA, INC. 63837 ALLERGAN USA, INC. 2019 second_quarter PHA Supporting proposals to strengthen safety standards and enforcement of the Drug Quality and Safety Act. Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE   1060000 0 0 2019-07-17T13:16:00.050000-04:00
2307246 KOUNTOUPES DENHAM CARR & REID, LLC a065be13-c491-4e6c-90f3-cc717aef4b5e Q2 KOUNTOUPES DENHAM CARR & REID, LLC 320918 ASSOCIATION FOR ACCESSIBLE MEDICINES (FORMERLY - GENERIC PHARMACEUTICAL ASSN) 2019 second_quarter PHA Policy matters related to generic pharmaceuticals and biosimilars, including H. R. 965 and S.340, the CREATES Act of 2019, and H. R. 985, the FAST Generics Act of 2019. H. R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019, and H. R. 938, the BLOCKING Act of 2019. Changes to the Risk Evaluation and Mitigation Strategies (REMS) program. Reimbursement rate for biosimilars. S. 1895, the Lower Health Care Costs Act. HOUSE OF REPRESENTATIVES,SENATE,White House Office 60000   0 0 2019-07-17T13:23:15.833000-04:00
2307555 KOUNTOUPES DENHAM CARR & REID, LLC 295cd029-5684-4e30-b130-f32999bf622f Q2 KOUNTOUPES DENHAM CARR & REID, LLC 320918 CVS HEALTH 2019 second_quarter PHA General education about the pharmacy benefit manager/pharmacy industry, including S.476, The Creating Transparency to Have Drug Rebates Unlocked (C-THRU)Act. Issues related to Risk Evaluation and Mitigation Strategies (REMS) program, including S.340 and H. R. 965, The CREATES Act. S. 1895, Lower Health Case Costs Act; S.1227, The Prescription Pricing for the People Act of 2019. HOUSE OF REPRESENTATIVES,SENATE,White House Office 60000   0 0 2019-07-17T14:21:21.340000-04:00
2307658 BLUE CROSS AND BLUE SHIELD OF FLORIDA, INC. 632c0aea-1637-4f05-aeda-6292e7eda6bd Q2 BLUE CROSS AND BLUE SHIELD OF FLORIDA, INC. 6382 BLUE CROSS AND BLUE SHIELD OF FLORIDA INC 2019 second_quarter PHA Opioids (Epidemic, Deterrence, Economic Impact Zones); CREATES Act; Drug Pricing; PBM/Prescription Drug Costs; Rx Rebates; Direct to Consumer Rx Advertising; Biosimilars; Drug Approval HR 965 (116th Congress), CREATES Act of 2019, by Rep. David Cicilline (D-RI). To promote competition in the market for drugs and biological products by facilitating the timely entry of lower-cost generic and biosimilar versions of those drugs and biological products. HR 1499 (116th Congress), Protecting Consumer Access to Generic Drugs Act of 2019, by Rep. Bobby Rush (D-IL). To prohibit brand name drug manufacturers from compensating generic drug manufacturers to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable product manufacturers to delay entry of biosimilar and interchangeable products, and for other purposes. HR 1503 (116th Congress), Orange Book Transparency Act of 2019, by Rep. Robin Kelly (D-IL). To amend the Federal Food, Drug, and Cosmetic Act regarding the list under section 505(j)(7) of the Federal Food, Drug, and Cosmetic Act, and for other purposes. HR 1520 (116th Congress), Purple Book Continuity Act of 2019, by Rep. Anna Eshoo (D-CA). To amend the Public Health Service Act to provide for the publication of a list of licensed biological products, and for other purposes. Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),Office of Management & Budget (OMB),Office of Personnel Management (OPM),SENATE,Treasury, Dept of,White House Office   360000 0 0 2019-07-17T14:40:05.623000-04:00
2307669 KOUNTOUPES DENHAM CARR & REID, LLC 5e61b84a-8855-4636-907c-75eaec60e71d Q2 KOUNTOUPES DENHAM CARR & REID, LLC 320918 GLENMARK PHARMACEUTICALS, INC., USA 2019 second_quarter PHA General information about the company and the industry. Issues related to affordability and pricing of pharmaceuticals. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2019-07-17T14:41:09.140000-04:00
2307728 UNIVERSITY OF IOWA 70660f97-568d-4ebd-bc39-ec7ec2c45a5b Q2 UNIVERSITY OF IOWA 49191 UNIVERSITY OF IOWA 2019 second_quarter PHA N/A Commerce, Dept of (DOC),Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE   50000 0 0 2019-07-17T14:46:24.017000-04:00
2307741 BLUE CROSS AND BLUE SHIELD OF FLORIDA, INC. 30eef3e8-7aa1-40aa-8136-3e4b1cb14bcc 2A BLUE CROSS AND BLUE SHIELD OF FLORIDA, INC. 6382 BLUE CROSS AND BLUE SHIELD OF FLORIDA INC 2019 second_quarter PHA Opioids (Epidemic, Deterrence, Economic Impact Zones); CREATES Act; Drug Pricing; PBM/Prescription Drug Costs; Rx Rebates; Direct to Consumer Rx Advertising; Biosimilars; Drug Approval HR 965 (116th Congress), CREATES Act of 2019, by Rep. David Cicilline (D-RI). To promote competition in the market for drugs and biological products by facilitating the timely entry of lower-cost generic and biosimilar versions of those drugs and biological products. HR 1499 (116th Congress), Protecting Consumer Access to Generic Drugs Act of 2019, by Rep. Bobby Rush (D-IL). To prohibit brand name drug manufacturers from compensating generic drug manufacturers to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable product manufacturers to delay entry of biosimilar and interchangeable products, and for other purposes. HR 1503 (116th Congress), Orange Book Transparency Act of 2019, by Rep. Robin Kelly (D-IL). To amend the Federal Food, Drug, and Cosmetic Act regarding the list under section 505(j)(7) of the Federal Food, Drug, and Cosmetic Act, and for other purposes. HR 1520 (116th Congress), Purple Book Continuity Act of 2019, by Rep. Anna Eshoo (D-CA). To amend the Public Health Service Act to provide for the publication of a list of licensed biological products, and for other purposes. Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),Office of Management & Budget (OMB),Office of Personnel Management (OPM),SENATE,Treasury, Dept of,White House Office   370000 0 0 2019-07-17T14:47:25.483000-04:00
2307749 ACG ADVOCACY 0cf13f50-de54-4b70-b484-974096164031 Q2 ACG ADVOCACY 2057 NATIONAL ASSOCIATION OF CHAIN DRUG STORES 2019 second_quarter PHA Advocacy on Medicare and Medicaid pharmacy coverage and reimbursement issues. Advocating for coverage of pharmacists services under Medicare Part B. Advocating for the passage of legislation that curbs prescription drug abuse while protecting patient access to medication. Advocating for fair and accurate Medicaid pharmacy reimbursement. Advocating for Medicare Part D changes that increase beneficiary eligibility for medication therapy management. Issues related to pharmacy reimbursement for 21st Century Cures. Issues regarding TriCare coverage for pharmacies. Issues regarding direct and indirect renumeration under Medicare Part D plans. Executive Office of the President (EOP),HOUSE OF REPRESENTATIVES,SENATE 80000   0 0 2019-07-17T14:49:28.843000-04:00
2307784 ELI LILLY AND COMPANY 4ad9d4e5-84d5-4128-9794-c7adc04f0255 2A ELI LILLY AND COMPANY 13392 ELI LILLY AND COMPANY 2019 second_quarter PHA Hospital discounts; 340B program Commerce, Dept of (DOC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),Office of Management & Budget (OMB),SENATE,State, Dept of (DOS),U.S. Trade Representative (USTR)   2330000 0 0 2019-07-17T14:56:44.390000-04:00
2307857 PRIME THERAPEUTICS c0cce518-5866-4f11-94e9-a014d0b75f05 Q2 PRIME THERAPEUTICS 400339576 PRIME THERAPEUTICS 2019 second_quarter PHA Request for Information: HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs, provisions affecting market competition for prescription drugs and the drug supply chain. HOUSE OF REPRESENTATIVES,SENATE   83000 0 0 2019-07-17T15:07:03.857000-04:00
2308041 ACG ADVOCACY 0f9d9d6d-0eb5-4b10-8c83-9803bdc51c8b Q2 ACG ADVOCACY 2057 GENENTECH INC 2019 second_quarter PHA Drug Pricing Issues. Executive Office of the President (EOP),HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2019-07-17T15:48:14.747000-04:00
2308084 HEALTHCARE DISTRIBUTION ALLIANCE(HDA)(FORMERLY HEALTHCARE DISTRIBUTION MANAGEMENT ASSOCIATION (HDMA) a24953e9-d4d4-494e-991b-0914a4e98dff Q2 HEALTHCARE DISTRIBUTION ALLIANCE(HDA)(FORMERLY HEALTHCARE DISTRIBUTION MANAGEMENT ASSOCIATION (HDMA) 28776 HEALTHCARE DISTRIBUTION ALLIANCE (FORMERLY - HDMA) 2019 second_quarter PHA Opioid Abuse - General issues related to opioid abuse (implementation of Public Law 115-271) Issues related to ARCOS data and suspicious order record requirements and reporting Importation of Prescription Drugs (HR 447, HR 478, HR 1478, S 61, S 97, S 658, S 844) Implementation of Public Law 113-54 (DSCSA) Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE   312426 0 0 2019-07-17T15:55:29.887000-04:00
2308121 OLSSON, FRANK, WEEDA, TERMAN & MATZ, PC 2d1a07e6-dd70-4edf-b314-7d95f0caddeb Q2 OLSSON, FRANK, WEEDA, TERMAN & MATZ, PC 30212 NATIONAL ASSOCIATION OF CHAIN DRUG STORES 2019 second_quarter PHA Drug pricing, Direct and Indirect remuneration fees, Medicare Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2019-07-17T16:02:42.467000-04:00
2308436 ROCK & ASSOCIATES 47c0787f-c78c-45cc-9fdd-d7761415fd1b Q2 ROCK & ASSOCIATES 33545 BRAIDWOOD MANAGEMENT, INC. 2019 second_quarter PHA H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2019-07-17T17:33:45.307000-04:00
2308449 ROCK & ASSOCIATES 4544c73b-aea9-455b-925a-23969f8a466c Q2 ROCK & ASSOCIATES 33545 VETERINARY PHARMACIES OF AMERICA, INC. 2019 second_quarter PHA H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding. HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2019-07-17T17:41:48.530000-04:00
2308458 ROCK & ASSOCIATES ea54e812-e7d2-4d25-a46f-a2c5954d81d5 Q2 ROCK & ASSOCIATES 33545 WEDGEWOOD VILLAGE PHARMACY, INC. 2019 second_quarter PHA H.R. 1959, Preserving Patient Access to Compounded Medications Act of 2019. HOUSE OF REPRESENTATIVES,SENATE 22500   0 0 2019-07-17T17:43:50.653000-04:00
2308464 ROCK & ASSOCIATES 69a285b5-cf3c-46ed-a5b9-5eb7add68885 Q2 ROCK & ASSOCIATES 33545 WOMEN'S INTERNATIONAL PHARMACY 2019 second_quarter PHA H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding. Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2019-07-17T17:44:53.483000-04:00
2308468 ROCK & ASSOCIATES a3aa16bc-48ce-4245-8e68-76e2510ad4b9 Q2 ROCK & ASSOCIATES 33545 WELLNESS PHARMACY 2019 second_quarter PHA H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2019-07-17T17:46:54.217000-04:00
2308476 ROCK & ASSOCIATES e461757f-9de3-45de-b9a2-f50db8f6017e Q2 ROCK & ASSOCIATES 33545 PRECISION PHARMACY 2019 second_quarter PHA H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding. HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2019-07-17T17:47:56.297000-04:00
2308594 GOVERNMENT COUNSEL, LLC 178e3b54-776c-4251-8992-63487d524190 Q2 GOVERNMENT COUNSEL, LLC 401105070 HEALTHCARE DISTRIBUTION ALLIANCE 2019 second_quarter PHA Issues related to ARCOS data and suspicious order record requirements and reporting;importation of prescription drugs (HR 447, HR 478, HR 1478, S 61, S 97, S 658, S 844); implementation of Public Law 113-54 (DSCSA). HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2019-07-17T18:49:22.787000-04:00
2308793 FIERCE GOVERNMENT RELATIONS 4b653d06-8140-4259-b46d-c68d24d456cc Q2 FIERCE GOVERNMENT RELATIONS 401103500 SUN PHARMACEUTICAL INDUSTRIES, INC. 2019 second_quarter PHA S. 340 - CREATES Act of 2019, Issues relating to biodefense, S. 64 - Preserve Access to Affordable Generics and Biosimilars Act SENATE 60000   0 0 2019-07-18T09:11:44.230000-04:00
2309176 FIERCE GOVERNMENT RELATIONS 80259229-38d2-496e-afc3-5a6d4800f92e Q2 FIERCE GOVERNMENT RELATIONS 401103500 ASSOCIATION OF ACCESSIBLE MEDICINES (FORMERLY KNOWN AS GPHA) 2019 second_quarter PHA Issues relating to generic drugs, drug pricing, S. 340 - CREATES Act of 2019, Patent Abuse, S. 64- Preserve Access to Affordable Generics and Biosimilars Act, S. 1895- Lower Health Care Costs Act- Sec. 205, H.R. 965- CREATES Act of 2019 HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2019-07-18T10:25:05.347000-04:00
2309476 NATIONAL COMMUNITY PHARMACISTS ASSOCIATION 0cfa618b-a27b-458d-a9da-fb09b3161b1e Q2 NATIONAL COMMUNITY PHARMACISTS ASSOCIATION 27478 NATIONAL COMMUNITY PHARMACISTS ASSOCIATION 2019 second_quarter PHA H.R. 1959, Preserving Patient Access to Compounded Medications Act of 2019; H.R. 2376 / S. 1227, Prescription Pricing for the People Act of 2019; H.R. 3223 / S. 1532, Pharmacy Benefit Manager Accountability Study Act of 2019; Centers For Medicare and Medicaid Services (CMS),Defense, Dept of (DOD),Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Government Accountability Office (GAO),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Internal Revenue Service (IRS),Medicare Payment Advisory Commission (MedPAC),Office of Management & Budget (OMB),Office of Natl Drug Control Policy (NDCP),SENATE,Small Business Administration (SBA),Substance Abuse & Mental Health Services Administration (SAMHSA),White House Office   300000 0 0 2019-07-18T11:10:57.650000-04:00
2309750 BALLARD PARTNERS 5c16994e-5584-41a7-926f-19d533c8a504 Q2 BALLARD PARTNERS 401104288 LABORATORY CORPORATIONS OF AMERICA HOLDINGS 2019 second_quarter PHA Clinical Lab Rates Health & Human Services, Dept of (HHS),White House Office 80000   0 0 2019-07-18T12:13:44.560000-04:00
2309985 THE MCSWANE GROUP 0dcad4d7-b9c6-4a5d-8ff5-f84714f5a5fa Q2 THE MCSWANE GROUP 401105094 NATIONAL ASSOCIATION OF CHAIN DRUG STORES 2019 second_quarter PHA direct and indirect remuneration (DIR) fee reform HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2019-07-18T13:10:14.473000-04:00
2310044 THE MCSWANE GROUP 583b9c67-2212-424a-aac8-d7ba83aec7f8 2T THE MCSWANE GROUP 401105094 NATIONAL ASSOCIATION OF CHAIN DRUG STORES 2019 second_quarter PHA direct and indirect remuneration (DIR) fee reform HOUSE OF REPRESENTATIVES,SENATE 10000   0 1 2019-07-18T13:21:34.990000-04:00
2310162 ASSOCIATION FOR ACCESSIBLE MEDICINES e857a1fd-989b-4cd4-b0a6-589f7fe82f75 Q2 ASSOCIATION FOR ACCESSIBLE MEDICINES 16032 ASSOCIATION FOR ACCESSIBLE MEDICINES 2019 second_quarter PHA Implementation of Food and Drug Administration Reauthorization Act (FDARA). Generic Drug User Fee Amendments (GDUFA). Biosimilar User Fee Act (BsUFA). Labeling of Generic Drugs. Drug Compounding. Drug Shortages. Biosimilars Naming. Biosimilars Insulin. Pass Through Payments for Biosimilars. Prescription Drug Costs. American Patients First: The Trump Administration Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs. Proposed Anti-Kickback Statute (AKS) Rebates. FDA Citizen Petitions. H.R.985: FAST Generics Act of 2019. H.R.1506: FAIR Generics Act. H.R.1503: Orange Book Transparency Act of 2019. H.R.1520: Purple Book Continuity Act of 2019. S.61: Safe and Affordable Drugs from Canada Act of 2019. S.64: Preserve Access to Affordable Generics and Biosimilars Act. S.1416: Affordable Prescriptions for Patients Act of 2019. S.1224: Stop STALLING Act. H.R.447/S.97: Affordable and Safe Prescription Drug Importation Act. S.124: Freedom to Compete Act. H.R.1499: Protecting Consumer Access to Generic Drugs Act of 2019. H.R.938: Bringing Low-Cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019. H.R.465/S.102: Prescription Drug Price Relief Act of 2019. H.R.1093/S. 378: Stop Price Gouging Act. S.474: Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act of 2019. S.475: Reducing Existing Costs Associated with Pharmaceuticals for Seniors (RxCAP) Act of 2019. S.476: Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019. S.440: Preserving Access to Cost Effective Drugs (PACED) Act. S.1895: Lower Health Care Costs Act. H.R.965/S.340: CREATES Act of 2019. Public Law 115-123: Bipartisan Budget Act of 2018. Risk Evaluation and Mitigation Strategies (REMS). Pharmaceutical Exclusivity. Biologic Exclusivity. H.R.3379: Price Relief, Innovation, and Competition for Essential Drugs Act. S.659: Biologic Patent Transparency Act. Biologics Price Competition and Innovation Act (BPCIA). Public Law 115-52: FDA Reauthorization Act of 2017. Centers For Medicare and Medicaid Services (CMS),Commerce, Dept of (DOC),Congressional Budget Office (CBO),Federal Trade Commission (FTC),Food & Drug Administration (FDA),Government Accountability Office (GAO),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),Patent & Trademark Office (PTO),SENATE,State, Dept of (DOS),U.S. Trade Representative (USTR)   1100000 0 0 2019-07-18T13:49:22.430000-04:00
2310326 BLUE CROSS AND BLUE SHIELD ASSOCIATION 8d7e9dc8-cc4f-4549-8d24-a205b6304a86 Q2 BLUE CROSS AND BLUE SHIELD ASSOCIATION 6358 BLUE CROSS AND BLUE SHIELD ASSOCIATION 2019 second_quarter PHA Opioids (Epidemic, Deterrence, Economic Impact Zones); CREATES Act;Drug Pricing; PBM/Prescription Drug Costs Rx Rebates; Direct-to-Consumer Rx Advertising;Rx Rebates; Biosimilars; Drug approval; H.R.1781 - 116th Congress (2019-2020) Payment Commission Data Act of 2019 Sponsor: Rep. Carter, Earl L. "Buddy" [R-GA-1] H.R.938 - 116th Congress (2019-2020) BLOCKING Act of 2019 Sponsor: Rep. Schrader, Kurt [D-OR-5] H.R.1520 - 116th Congress (2019-2020) Purple Book Continuity Act of 2019 Sponsor: Rep. Eshoo, Anna G. [D-CA-18] H.R.1503 - 116th Congress (2019-2020) Orange Book Transparency Act of 2019 Sponsor: Rep. Kelly, Robin L. [D-IL-2] H.R.1499 - 116th Congress (2019-2020) Protecting Consumer Access to Generic Drugs Act of 2019 Sponsor: Rep. Rush, Bobby L. [D-IL-1] H.R.965 - 116th Congress (2019-2020) CREATES Act of 2019 Sponsor: Rep. Cicilline, David N. [D-RI-1] Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),Office of Management & Budget (OMB),Office of Personnel Management (OPM),SENATE,Treasury, Dept of,White House Office   1890000 0 0 2019-07-18T14:24:15.433000-04:00
2310422 FARRAGUT PARTNERS LLP 2d54e5a8-fedd-417a-a4c6-52f9a94672ee Q2 FARRAGUT PARTNERS LLP 401103938 COMMUNITY ONCOLOGY ALLIANCE 2019 second_quarter PHA Issues related to pharmacy benefit managers. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 80000   0 0 2019-07-18T14:34:52.047000-04:00
2310451 KENT & O'CONNOR, INC. e43e3b45-7fb7-408b-a0fd-b83c0b836f86 Q2 KENT & O'CONNOR, INC. 21426 INTERNATIONAL WAREHOUSE LOGISTICS ASSOCIATION 2019 second_quarter PHA Legislation and regulations relating to drug and safety issues. Implementation of the Drug Supply Chain Security Act. Environmental Protection Agency (EPA),Federal Maritime Commission,Food & Drug Administration (FDA),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),Occupational Safety & Health Administration (OSHA),SENATE,Surface Transportation Board (STB),Transportation, Dept of (DOT),Transportation Security Administration (TSA),Treasury, Dept of,U.S. Customs & Border Protection 30000   0 0 2019-07-18T14:37:58.310000-04:00
2310461 MEHLMAN CONSULTING, INC. 55b547bb-14b0-4ff6-843f-895871ba828a Q2 MEHLMAN CONSULTING, INC. 284950 BLUE SHIELD OF CALIFORNIA 2019 second_quarter PHA Prescription drug pricing. Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2019-07-18T14:39:01.763000-04:00
2310751 MEHLMAN CONSULTING, INC. 21e8acc5-c5be-48b9-8602-e8c112169878 Q2 MEHLMAN CONSULTING, INC. 284950 AMERICA'S HEALTH INSURANCE PLANS 2019 second_quarter PHA Prescription drug pricing Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE,White House Office 80000   0 0 2019-07-18T15:04:35.110000-04:00
2311027 OREGON HEALTH & SCIENCE UNIVERSITY 46134fc8-ae8b-43c9-bdff-00d04cb125f2 Q2 OREGON HEALTH & SCIENCE UNIVERSITY 30291 OREGON HEALTH & SCIENCE UNIVERSITY 2019 second_quarter PHA 340b Drug Discount Program for safety net hospitals and Health Resources and Services Administration proposed omnibus guidance. HOUSE OF REPRESENTATIVES,SENATE   80000 0 0 2019-07-18T15:39:22.583000-04:00
2311045 PUBLIC CITIZEN 54d0a8ca-7b2e-4726-b59e-74d2642860d9 Q2 PUBLIC CITIZEN 32362 PUBLIC CITIZEN 2019 second_quarter PHA HR 1046/S 377-Medicare negotiation and competitive licensing act, HR 938-BLOCKING ACT, hr 965/s340- (creates ACT), HR 1503-Orange book transparency act, HR 1520-Purple book continuity act, HR 1499-Protecting consumer access to generic drugs act, S 64-preserve access to affordable generics and biosimilars act, drug pricing, HR 2113-Prescription drug STAR act, HR 1093/S 378 (Stop price gouging act, HR 1344-Competitive drugs act, HR 465/S 102-Prescription drug price relief act, HR-3379- PRICED act, affordable drug manufacturing act, S 1416-Affordable prescriptions to patients act, HR 2374/S 1224 (stop STALLING act) HR 2917 Opioid Crisis accountability act, S 1209-REMEDY ACT, hr 6505 Medicare Negotiation and competitive Licensing act, SEC 101-Patent reform legislation Federal Trade Commission (FTC),HOUSE OF REPRESENTATIVES,Securities & Exchange Commission (SEC),SENATE,U.S. Trade Representative (USTR)   110000 0 0 2019-07-18T15:39:24.177000-04:00
2311365 BLUE CROSS BLUE SHIELD OF MICHIGAN 3dca7968-ca8c-4d61-a1fc-4850dfc406eb Q2 BLUE CROSS BLUE SHIELD OF MICHIGAN 46676 BLUE CROSS BLUE SHIELD OF MICHIGAN 2019 second_quarter PHA Opioids (Epidemic, Deterrence, Economic Impact Zones); CREATES Act;Drug Pricing; PBM/Prescription Drug Costs Rx Rebates; Direct-to-Consumer Rx Advertising;Rx Rebates; Biosimilars; Drug approval; H.R.1520 - 116th Congress (2019-2020) Purple Book Continuity Act of 2019 Sponsor: Rep. Eshoo, Anna G. [D-CA-18] H.R.1503 - 116th Congress (2019-2020) Orange Book Transparency Act of 2019 Sponsor: Rep. Kelly, Robin L. [D-IL-2] H.R.1499 - 116th Congress (2019-2020) Protecting Consumer Access to Generic Drugs Act of 2019 Sponsor: Rep. Rush, Bobby L. [D-IL-1] H.R.965 - 116th Congress (2019-2020) CREATES Act of 2019 Sponsor: Rep. Cicilline, David N. [D-RI-1] HOUSE OF REPRESENTATIVES,SENATE   92595 0 0 2019-07-18T16:18:08.480000-04:00
2311969 BROYDRICK & ASSOCIATES 6ac1a22d-eac9-4859-b163-89d2ad215a43 Q2 BROYDRICK & ASSOCIATES 7268 EXELA PHARMA SCIENCES 2019 second_quarter PHA Drug shortages and FDA approval. USTR acceptance. Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2019-07-18T21:31:09.363000-04:00
2312001 BROYDRICK & ASSOCIATES 58d9be16-1b52-46ec-b3d6-9ce84f5472b7 Q2 BROYDRICK & ASSOCIATES 7268 TONIX PHARMACEUTICALS 2019 second_quarter PHA Funding new drug for PTSD. Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2019-07-18T22:05:23.507000-04:00
2312037 FORGE FEDERAL AFFAIRS LLC 2dc749ee-ef45-48a4-8892-124a1d16a698 Q2 FORGE FEDERAL AFFAIRS LLC 400865535 LILLY USA LLC 2019 second_quarter PHA Issues related to pricing of prescription drugs. Opposition to prescription drug importation and cuts to Medicare Part D funding. Support for funding of Department of Homeland Security drug interdiction efforts. HOUSE OF REPRESENTATIVES 20000   0 0 2019-07-18T23:08:42.810000-04:00
2312170 VAN SCOYOC ASSOCIATES ba03d842-659c-436d-aafa-c1e775dc4c85 Q2 VAN SCOYOC ASSOCIATES 39837 ZEBRA TECHNOLOGIES CORP. 2019 second_quarter PHA Public Law 113-54, Drug Quality and Security Act, Drug labeling implementation HOUSE OF REPRESENTATIVES,SENATE 120000   0 0 2019-07-19T05:24:33.583000-04:00
2312804 FAEGRE BAKER DANIELS CONSULTING b39586e7-3a70-437a-9670-317f6870b008 Q2 FAEGRE BAKER DANIELS CONSULTING 34158 NATIONAL ASSOCIATION OF BOARDS OF PHARMACY 2019 second_quarter PHA Pharmacy regulation; Prescription drug monitoring Centers For Disease Control & Prevention (CDC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),SENATE 110000   0 0 2019-07-19T09:28:17.187000-04:00

Next page

Advanced export

JSON shape: default, array, newline-delimited, object

CSV options:

CREATE TABLE lobbying_activities (
            id INTEGER PRIMARY KEY,
            filing_uuid TEXT NOT NULL,
            filing_type TEXT NOT NULL,
            registrant_name TEXT NOT NULL,
            registrant_id INTEGER,
            client_name TEXT NOT NULL,
            filing_year INTEGER NOT NULL,
            filing_period TEXT NOT NULL,
            issue_code TEXT,
            specific_issues TEXT,
            government_entities TEXT,
            income_amount INTEGER,
            expense_amount INTEGER,
            is_no_activity INTEGER DEFAULT 0,
            is_termination INTEGER DEFAULT 0,
            received_date TEXT,
            CONSTRAINT fk_activity_filing FOREIGN KEY (filing_uuid)
                REFERENCES lobbying_filings_raw(filing_uuid)
        );
CREATE INDEX idx_act_client_name ON lobbying_activities(client_name COLLATE NOCASE);
CREATE INDEX idx_act_issue_code ON lobbying_activities(issue_code);
CREATE INDEX idx_act_filing_year ON lobbying_activities(filing_year);
CREATE INDEX idx_act_filing_uuid ON lobbying_activities(filing_uuid);
Powered by Datasette · Queries took 2203.934ms · Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API